These findings underscore the significance of the radiomics approach in discerning and comprehending the distinctions between HER2-low and HER2-negative BC, shedding light on potential factors contributing to tumor heterogeneity and aggressiveness. The gene discussed is ERBB2; the disease is breast cancer.